Neurobiology of glycine transporters: From molecules to behavior

•GlyT1 is abundant in the neocortex, thalamus and hippocampus.•GlyT2 is markedly expressed in the brainstem, spinal cord and cerebellum.•GlyT1 is expressed in astrocytes and involved in glutamatergic neurotransmission.•GlyT2 is responsible for glycine uptake into glycinergic and GABAergic terminals.•GlyT1 transporters modulate glutamatergic neurotransmission through NMDAR.•GlyTs functional dysfunction is related to several neurological disorders. Glycine transporters (GlyTs) are Na+/Cl−-dependent neurotransmitter transporters, responsible for l-glycine uptake into the central nervous system. GlyTs are members of the solute carrier family 6 (SLC6) and comprise glycine transporter type 1 (SLC6A9; GlyT1) and glycine transporter type 2 (SLC6A5; Glyt2). GlyT1 and GlyT2 are expressed on both astrocytes and neurons, but their expression pattern in brain tissue is foremost related to neurotransmission. GlyT2 is markedly expressed in brainstem, spinal cord and cerebellum, where it is responsible for glycine uptake into glycinergic and GABAergic terminals. GlyT1 is abundant in neocortex, thalamus and hippocampus, where it is expressed in astrocytes, and involved in glutamatergic neurotransmission. Consequently, inhibition of GlyT1 transporters can modulate glutamatergic neurotransmission through NMDA receptors, suggesting an alternative therapeutic strategy. In this review, we focus on recent progress in the understanding of GlyTs role in brain function and in various diseases, such as epilepsy, hyperekplexia, neuropathic pain, drug addiction, schizophrenia and stroke, as well as in neurodegenerative disorders.